- Home
- GCMG vs UPB Comparison
GCMG vs UPB Comparison
Compare GCMG & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCMG
- UPB
- Stock Information
- Founded
- GCMG 1971
- UPB 2021
- Country
- GCMG United States
- UPB United States
- Employees
- GCMG N/A
- UPB N/A
- Industry
- GCMG Finance/Investors Services
- UPB
- Sector
- GCMG Finance
- UPB
- Exchange
- GCMG Nasdaq
- UPB NYSE
- Market Cap
- GCMG 631.4M
- UPB 521.3M
- IPO Year
- GCMG N/A
- UPB 2024
- Fundamental
- Price
- GCMG $12.50
- UPB $11.27
- Analyst Decision
- GCMG Hold
- UPB Strong Buy
- Analyst Count
- GCMG 5
- UPB 4
- Target Price
- GCMG $13.60
- UPB $56.50
- AVG Volume (30 Days)
- GCMG 434.1K
- UPB 364.5K
- Earning Date
- GCMG 05-07-2025
- UPB 05-06-2025
- Dividend Yield
- GCMG 3.52%
- UPB N/A
- EPS Growth
- GCMG N/A
- UPB N/A
- EPS
- GCMG 0.14
- UPB N/A
- Revenue
- GCMG $530,455,000.00
- UPB $2,296,000.00
- Revenue This Year
- GCMG $3.62
- UPB N/A
- Revenue Next Year
- GCMG $12.02
- UPB N/A
- P/E Ratio
- GCMG $91.73
- UPB N/A
- Revenue Growth
- GCMG 17.38
- UPB N/A
- 52 Week Low
- GCMG $9.25
- UPB $5.14
- 52 Week High
- GCMG $14.48
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- GCMG 47.05
- UPB N/A
- Support Level
- GCMG $12.38
- UPB N/A
- Resistance Level
- GCMG $12.92
- UPB N/A
- Average True Range (ATR)
- GCMG 0.25
- UPB 0.00
- MACD
- GCMG -0.00
- UPB 0.00
- Stochastic Oscillator
- GCMG 50.00
- UPB 0.00
About GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.